Skip to content
← Back to this collection

PUBLICATIONS · 16873669

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2006 Nov 15
First author
van Oers MH

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      van Oers MH
      type
      Author
    2. name
      Klasa R
      type
      Author
    3. name
      Marcus RE
      type
      Author
    4. name
      Wolf M
      type
      Author
    5. name
      Kimby E
      type
      Author
    6. name
      Gascoyne RD
      type
      Author
    7. name
      Jack A
      type
      Author
    8. name
      Van't Veer M
      type
      Author
    9. name
      Vranovsky A
      type
      Author
    10. name
      Holte H
      type
      Author
    11. name
      van Glabbeke M
      type
      Author
    12. name
      Teodorovic I
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      van Oers MH
      type
      Author
    2. name
      Klasa R
      type
      Author
    3. name
      Marcus RE
      type
      Author
    4. name
      Wolf M
      type
      Author
    5. name
      Kimby E
      type
      Author
    6. name
      Gascoyne RD
      type
      Author
    7. name
      Jack A
      type
      Author
    8. name
      Van't Veer M
      type
      Author
    9. name
      Vranovsky A
      type
      Author
    10. name
      Holte H
      type
      Author
    11. name
      van Glabbeke M
      type
      Author
    12. name
      Teodorovic I
      type
      Author
    bibliography ids
    1. nci-bib-3faae9db9715159181150a58
    book metadata
    content sha256
    aa9a148ed63c5002425df75fb8e839eb9b5d26ac5bff887cafb8fe15926feab0
    document type
    citation
    dois
    1. 10.1182/blood-2006-05-021113
    electronic publication date
    display
    2006 Jul 27
    precision
    day
    year
    2006
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:16873669
    immutable id
    pubmed:16873669@aa9a148ed63c5002425df75fb8e839eb9b5d26ac5bff887cafb8fe15926feab0
    journal
    abbreviation
    Blood
    issn electronic
    Source null
    issn print
    0006-4971
    issue
    10
    name
    Blood
    nlm unique id
    7603509
    pages
    3295-301
    volume
    108
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      16873669
      provenance
      batch id
      2c499a3b9f4867a74c49
      provider
      NCBI PubMed ESummary
      record sha256
      69d4cfeda929204f1703963603d212a368cb2b26a9aba303923659e552851559
      response sha256
      3b299651c5c5270455877b65b6e5acff71ad5f85103b7f9582efe63c52588326
      retrieved at
      2026-09-09T23:46:08.887541+00:00
      publication date
      display
      2006 Nov 15
      precision
      day
      year
      2006
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Randomized Controlled Trial
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/16873669/
      title
      Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

      Preserved source evidence · Independent clinical review pending · Not medical advice